These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18922296)

  • 1. Human papillomavirus vaccine efficacy: aligning expectations with reality.
    Smith-McCune KK
    Gynecol Oncol; 2008 Oct; 111(1):1-2. PubMed ID: 18922296
    [No Abstract]   [Full Text] [Related]  

  • 2. Gynaecological cancer: HPV vaccine: is age just a number?
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243
    [No Abstract]   [Full Text] [Related]  

  • 3. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.
    Frederick PJ; Huh WK;
    Expert Rev Anticancer Ther; 2008 May; 8(5):701-5. PubMed ID: 18471043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HPV vaccination and cervical cancer screening].
    Sigurdsson K
    Laeknabladid; 2007 Dec; 93(12):819, 821. PubMed ID: 18057470
    [No Abstract]   [Full Text] [Related]  

  • 6. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine.
    Di Mario S; Basevi V; Borsari S; Balduzzi S; Magrini N
    Lancet Oncol; 2012 Feb; 13(2):e50; author reply e50. PubMed ID: 22300857
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccination protects against invasive HPV-associated cancers.
    Luostarinen T; Apter D; Dillner J; Eriksson T; Harjula K; Natunen K; Paavonen J; Pukkala E; Lehtinen M
    Int J Cancer; 2018 May; 142(10):2186-2187. PubMed ID: 29280138
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cervical carcinoma and the vaccination experience with Cervarix].
    Berberova M
    Akush Ginekol (Sofiia); 2012; 51 Suppl 1():4-5. PubMed ID: 23236670
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.
    Harper DM
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S11-7. PubMed ID: 18649932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Success of HPV vaccination is now a matter of coverage.
    Schiffman M; Wacholder S
    Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169
    [No Abstract]   [Full Text] [Related]  

  • 11. Cervical cancer vaccine development.
    Frazer IH
    Sex Health; 2010 Sep; 7(3):230-4. PubMed ID: 20719210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccine against human papillomavirus : PATRICIA Study (PApilloma TRIal against Cancer In young Adults)].
    Kaufmann AM; Nitschmann S
    Internist (Berl); 2010 Mar; 51(3):410, 412-3. PubMed ID: 20127302
    [No Abstract]   [Full Text] [Related]  

  • 13. Cervical cancer vaccination: the real meaning of cross-protection and its impact on the prevention.
    De Carvalho NS
    Vaccine; 2008 Nov; 26(50):6293-4. PubMed ID: 18804508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinating adolescents and young women against cancer of the cervix.
    Hilgers RD; Wyatt SW
    J Ky Med Assoc; 2007 May; 105(5):215-6. PubMed ID: 17566465
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.
    Tota JE; Struyf F; Merikukka M; Gonzalez P; Kreimer AR; Bi D; Castellsagué X; de Carvalho NS; Garland SM; Harper DM; Karkada N; Peters K; Pope WAJ; Porras C; Quint W; Rodriguez AC; Schiffman M; Schussler J; Skinner SR; Teixeira JC; Wheeler CM; Herrero R; Hildesheim A; Lehtinen M;
    J Natl Cancer Inst; 2017 Jan; 109(7):. PubMed ID: 28132019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for cervical cancer: controversy and contention or thoughtful analysis.
    Frable WJ
    Cancer; 2007 Jun; 111(3):143-4. PubMed ID: 17487849
    [No Abstract]   [Full Text] [Related]  

  • 17. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
    Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
    BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.
    Cuzick J; Castañón A; Sasieni P
    Br J Cancer; 2010 Mar; 102(5):933-9. PubMed ID: 20104226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.